Back to research feed

European radiology

July 17, 2026 Ā· via Europe PMC

Biological effects of <sup>18</sup>F-FDG administration and CT dose during PET/CT: chromosomal aberrations in a two-center prospective observational study.

Kawashima Y, Kinugasa Y, Ishibashi M, +19 more, Tashiro S.

Observational StudyOpen access

AI summary — for doctors, generated from the abstract only

Standard-dose CT, not FDG, was associated with chromosomal damage in blood lymphocytes during PET/CT, supporting use of reduced-dose CT protocols.

What was studied

Prospective two-centre observational study of patients undergoing clinically indicated FDG-PET/CT with reduced-dose or standard-dose CT, measuring unstable chromosomal aberrations in lymphocytes before FDG, after FDG and after CT.

Key findings

  • 101 patients were enrolled at the reduced-dose centre and 56 at the standard-dose centre (156 evaluable)
  • FDG administration did not significantly increase chromosomal aberrations at either centre
  • After CT, aberrations did not rise significantly with the reduced-dose protocol but did with the standard-dose protocol (p = 0.016)
  • After adjustment, CT effective dose, but not FDG dose, was independently associated with aberration frequency; age and prior chemotherapy also mattered

Clinical relevance

The findings give a biological argument for CT dose optimisation and wider use of reduced-dose CT in PET/CT when clinically appropriate.

Who should care

Radiodiagnosis/Radiology

Limitations

Observational, with protocols confounded with centre (one dose protocol per site); chromosomal aberrations are a surrogate marker and clinical consequences were not measured.

CT dose, rather than FDG, appeared to drive measurable lymphocyte chromosomal changes, supporting dose optimisation.

This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.

Abstract

Objective

To assess the radiation effects of internal 18F-fluorodeoxyglucose (FDG) administration and external CT exposures during PET/CT, using reduced-dose and standard-dose CT protocols, on chromosomes in peripheral blood lymphocytes (PBLs).

Materials and methods

This prospective two-center observational study included patients undergoing clinically indicated FDG-PET/CT using different CT dose protocols. Peripheral blood was sampled at three time points: before FDG administration, after FDG administration, and after CT acquisition. Unstable chromosomal aberrations (CAs) in PBLs were quantified at each time point. Non-parametric tests were used for group comparisons, and associations between radiation dose parameters and changes in CAs were evaluated using generalized linear mixed-effects models.

Results

A total of 101 consecutive patients were enrolled in the reduced-dose protocol center (Center RD; mean age 70 ± 9 years [standard deviation], 55 men) and 56 patients in the standard-dose protocol center (Center SD; 64 ± 11 years, 31 men). The CA-evaluable population comprised 101 patients in Center RD and 55 patients in Center SD. FDG administration did not significantly increase CAs at either center. Following CT acquisition, no significant increase in CAs was observed with the reduced-dose protocol, whereas CAs increased significantly with the standard-dose protocol (Center SD: p = 0.016).

Conclusion

FDG administration had no detectable impact on CAs, whereas CT effective dose was associated with CA frequency after multivariable adjustment, with no evidence of a synergistic interaction with FDG. These findings support CT dose optimization and the use of reduced-dose CT protocols in PET/CT when clinically appropriate.

Key points

Question How do internal 18F-fluorodeoxyglucose (FDG) and external CT exposures during PET/CT affect chromosomes, and how do these effects differ between reduced- and standard-dose CT protocols? Findings Chromosomal aberrations increased after standard-dose PET/CT, and CT effective dose, but not FDG effective dose, was independently associated with chromosomal aberration frequency after multivariable adjustment. Clinical relevance CT effective dose was independently associated with chromosomal aberration frequency, while age and prior chemotherapy also influenced CA frequency. This provides biological justification for CT dose optimization and broader use of reduced-dose PET/CT when clinically appropriate.

DOI

10.1007/s00330-026-12731-0

PMID

42469535

PMCID

PMC13661646

Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.

Back to the research feed

Create a free account Ā· Sign in